Sodium selenite supplementation does not fully restore oxidative stress-induced deiodinase dysfunction : implications for the nonthyroidal illness syndrome by Wajner, Simone Magagnin et al.
Redox Biology 6 (2015) 436–445Contents lists available at ScienceDirectRedox Biologyhttp://d
2213-23
n Corr
Alegre,
E-mjournal homepage: www.elsevier.com/locate/redoxResearch PaperSodium selenite supplementation does not fully restore oxidative
stress-induced deiodinase dysfunction: Implications for the
nonthyroidal illness syndrome
Simone Magagnin Wajner, Helena Cecin Rohenkohl, Tulio Serrano, Ana Luiza Maia n
Thyroid Section, Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazila r t i c l e i n f o
Article history:
Received 28 August 2015
Received in revised form
4 September 2015
Accepted 7 September 2015
Available online 9 September 2015
Keywords:
Deiodinases
Sodium selenite
Thyroid hormone
Nonthyroidal illness syndromex.doi.org/10.1016/j.redox.2015.09.002
17/& 2015 Elsevier B.V.. Published by Elsevier
espondence to: Serviço de Endocrinologia, H
Rua Ramiro Barcelos, 2350, CEP 90035-003 P
ail address: almaia@ufrgs.br (A.L. Maia).a b s t r a c t
Nonthyroidal illness syndrome (NTIS) is marked by low T3 and high reverse T3 levels. The physio-
pathology is poorly understood but involves oxidative stress-induced disruption of the iodothyronine
deiodinases, which activate or inactivate thyroid hormones. Selenium, an essential trace element, exerts
antioxidant function mainly through the thioredoxin reductase (TRx) and glutathione peroxidase (GPx)
redox-regulating systems. We evaluated the effect of sodium selenite on IL6-induced disruption on
deiodinase function. Cell lines expressing endogenous deiodinases type 1(D1), 2(D2) or 3(D3) (HepG2,
MSTO, and MCF-7 cells, respectively) were used in an intact cell model that mimics the deiodination
process under physiological conditions of substrate and cofactor, in the presence or not of IL6, with or
without selenite. Deiodinase activity was quantified by the amount of iodine-125 in the medium (D1 and
D2) or by ion-exchange chromatography (D3). Oxidative stress was evaluated by measuring reactive
species (RS), carbonyl content as well as enzymatic and non-enzymatic antioxidant defenses. Results: IL6
induced ROS and carbonyl content in all 3 cell lines (all Po0.001). Increased ROS was paralleled by D1
and D2-decreased T3-production (Po0.01) and increased D3-catalyzed T3-inactivation (Po0.001). Se-
lenite decreases the IL6-induced ROS and carbonyl content, while enhances Gpx and Trx activities.
Nevertheless, it failed on restoring D1 or D2 function and only attenuates D3 activation (Po0.05). In
conclusion, although sodium selenite reduces IL6-induced redox imbalance it does not fully repair
deiodinase function. These results shed light on NTIS physiopathology and might explain why low T3
levels are unaffected by selenium supplementation in sick patients.
& 2015 Elsevier B.V.. Published by Elsevier B.V. All rights reserved.1. Introduction
The conversion of peripheral thyroxine (T4) to 3,5,3′-triio-
dothyronine (T3) accounts for 80% of all T3 produced in euthyroid
individuals. This critical step in thyroid hormone metabolism is
catalyzed by two enzymes, the type 1 (D1) and type 2 (D2) io-
dothyronine deiodinases, via outer-ring deiodination of the pro-
hormone T4. Type 3 iodothyronine deiodinase (D3) catalyzes the
inner (5)-ring deiodination of T4 and T3, thus inactivating thyroid
hormone activity [1]. The deiodination reactions are catalyzed by
an as yet undefined cofactor, probably a thiol, which acts as a re-
ducing agent, regenerating the active enzyme. All deiodinases
contain the amino acid selenocysteine in their active site, an es-
sential residue for efficient catalysis [2–4].
The nonthyroidal illness syndrome (NTIS) refers to changes inB.V. All rights reserved.
ospital de Clínicas de Porto
orto Alegre, RS, Brazil.peripheral thyroid hormone levels, characterized by low T3 and
high serum reverse T3 levels. This set of alterations is observed in
470% of critically ill patients in almost every form of illness and is
correlated with increased mortality [5,6]. Changes in deiodinase
activities have been postulated to play an important role in the
altered circulating levels of thyroid hormones in NTIS [7]. Cyto-
kines are elevated as a generalized response to illness and avail-
able data suggest that interleukin (IL)-1β, tumor necrosis factor-α
(TNFα) and, particularly IL6, play a central role in in NTIS [7]. The
increased levels of IL6 lead to increases in superoxide radical
(O2●) production through the enzyme complex of the NAD(P)H
oxidase system, a major pathway of increased reactive oxidative
species (ROS) generation [8]. The resulting oxidative environment
impairs D1 and D2 function while inducing the expression of D3
[9]. The decreases in D1 and D2 activities occur despite increases
in D1 and D2 protein levels, indicating that IL6-induced oxidative
stress decreases the catalytic activity of D1 and D2, possibly by
interfering with the effects of the yet unknown endogenous co-
factor(s). Indeed, N-acetylcysteine (NAC), an antioxidant that re-
stores intracellular reduced gluthatione (GSH) levels, prevents the
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Selenium, an essential trace element, has biological functions
vitally important to human health, exerting critical intracellular
antioxidant function mainly as selenoproteins [11–13]. Sodium
selenite, the most commonly used form of selenium supple-
mentation, acts through the enzymatic gluthatione peroxidase
(GPx) and thioredoxin (TRx) antioxidant defense system. The GPx
isoforms (GPx1–GPx6), implicated in maintaining cellular redox
homeostasis, reduce hydrogen and lipid peroxides, using GSH as
cofactor. TRx enzyme isoforms (TRx1–TRx3) play a role on the
cellular thiol-dependent redox mechanisms as a disulfide NAD(P)
H-dependent reducer [12–14]. Several studies have investigated
the effects of selenium supplementation in acutely ill patients;
however, the results of these studies are conflicting. While sele-
nium supplementation, most commonly with sodium selenite, did
not improve the clinical outcome or decrease mortality in some
studies [15,16], others reported an inverse correlation between
plasma selenium levels and sepsis-related organ failure assess-
ment [17]. Notably, decreases in selenium plasma levels have been
inversely correlated with survival rate in patients with severe
sepsis or septic shock [18,19].
The aim of the present study was to evaluate the antioxidative
effect of sodium selenite on the deiodination process under IL6-
induced oxidative stress in an intact cell system model that mi-
mics the NTIS.2. Methods
2.1. Reagents
Reagents were obtained from Invitrogen (Life Technologies Inc.,
NY, USA), Calbiochem-Novabiochem, or Sigma-Aldrich (St. Louis,
MO, USA). Outer ring-labeled [125I]T3 and [125I]T4 (specific activity
4400 Ci/mmol) were obtained from PerkinElmer (Boston, MA,
USA). Purification of [125I]T4 or [125I]T3 was performed on sepha-
dex LH-20 columns just before it was used to reduce 125I– to o1%.
2.2. Cell culture and condition studies
Human mesothelioma (MSTO-211H) and human embryonic
kidney epithelial (HEK-293) cell lines were obtained from Amer-
ican Type Culture Collection (Manassas, VA, USA). Hepatocarci-
noma (HepG2) and human breast carcinoma (MCF-7) cell lines,
were obtained from Banco de Células do Rio de Janeiro (RJ, Brazil).
MSTO-211 and MCF-7 cells were cultured in RPMI-1640 (Roswell
Park Memorial Institute) medium supplemented with 10% fetal
bovine serum, while HepG2 and HEK-293 cells were cultured in
Dulbecco's Modified Eagle Medium supplemented with 10% fetal
bovine serum. Cells were maintained at 37 °C in a humidified at-
mosphere of 5% CO2 and 95% air, and the culture medium was
changed three times per week. The passage number of all cell lines
was less then 10–15 at the time of experiments.
In all the experiments to evaluate the effect of IL6 and sodium
selenite on intracellular oxidative parameters, enzyme activity and
mRNA cells were cultured with IL6, in an attempt to reproduce the
pathophysiological conditions as observed in NTIS patients [20],
with or without 100 nM sodium selenite (Na(2)SeO(3)) per 24 h
[21]. In all experiments 20 mM NAC was used as control, since it is
able to completely restore deiodinase function in the presence of
augmented reactive oxygen species [9].
2.3. Deiodinase activity for D1 and D2 in intact cells
Intact cell assay for D1 and D2 was performed as previously
described [22]. Cells were cultured for 24 h in 1 mL serum-free0.1% BSA plus 740 nM of total T4 (resulting in an FT4 concentration
of 2.7%; [23]), including approximately 100,000 cpm/mL [125I]T4 in
the presence or not of IL6, sodium selenite or NAC. Experiments
were performed in duplicate or triplicate for each condition and
repeated at least three times. At the completion of the experiment,
300 μL medium were removed, added to 200 μL horse serum and
protein precipitated by 100 μL 50% trichloroacetic acid (TCA). After
vortexing, tubes were centrifuged at 12,000 g for 2 min. The 125I–
generated was expressed as the fraction of the total T4 counts
minus the nonspecific deiodination in untransfected HEK-293
cells, which does not express any deiodinase activity (o5% of total
[125I]T4 counts), and corrected for the 50% reduction in the specific
activity relative to T4. Net T3 production was calculated by mul-
tiplying the fractional conversion by the T4 concentration in the
media (740 pM) and expressed as total T3 production/mg protein
per 24 h. Results were expressed as iodide production. Using high-
performance liquid chromatography, the authors previously de-
monstrated that net iodide release in this particular system – al-
though not in skeletal muscle – is specific and equivalent to T3
production [22,24].
2.4. Deiodinase activity for D3 in intact cells
For the studies with D3, cells in 6-well plates were cultured for
24 h in 1 mL serum-free 0.5% BSA (resulting in an FT3 fraction of
3.5%; [25]) in DMEM plus 195 pM T3 (FT3, 7 pM), including
approximately 200,000 cpm/mL [125I]T3 in the presence or not of
IL6, sodium selenite or NAC. Sephadex LH-20 chromatography was
used to measure the D3 activity in intact cells [9]. Briefly, at
completion of the experiment, 300 μL medium was collected, and
the reaction was stopped with 200 μL horse serum and 100 μL 50%
TCA, followed by centrifugation at 12,000 g for 2 min to precipitate
the non-metabolized [125I]T3. The supernatant was used for the
determination of [125I]T2 and [125I]T1 produced. The LH-20 col-
umn (bed volume 2 mL) was equilibrated with 1:1 0.1 M HCl, an
equal volume of 0.1 M HCl was added to 500 μL samples and the
mixture was then applied. Stepwise elution was performed by
successive application of 21 mL 0.1 M HCl (for 125I– release),
61 mL 20% ethanol ([125I] for T1 release), and 41 mL 50%
ethanol in 0.1 M NaOH (1:1 v/v [125I] for T2 release). The 1 mL
fractions were collected and counted for radioactivity. Results are
presented as the mean values derived from at least two in-
dependent experiments. Nonspecific deiodination was o1.5%. Net
D3 activity was calculated by multiplying the fractional conversion
by the T3 concentration in the media and expressed as T3 in-
activation (fmol/mg protein per 24 h). The reaction was saturated
by excess unlabeled T3.
2.5. Real-time PCR
Using the same incubation conditions above, after 24 h in-
cubation total RNA was extracted from MSTO-211, HepG2 and
MCF-7 cells with an RNeasy kit (Qiagen, Hilden, Germany) and
used to synthesize complementary DNA (cDNA) (SuperScript First-
Strand Synthesis System for RT-PCR; Invitrogen). The generated
cDNAs were used in a real-time PCR with a SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA) in ABI Prism 7500
Sequence Detection System (Applied Biosystems). Standard curves
representing five-point serial dilutions of cDNA of the experi-
mental and control groups were analyzed and used as calibrators
of the relative quantification of product generated in the ex-
ponential phase of the amplification curve. The r2 was 40.99, and
the amplification efficiency varied between 80% and 100%. Sam-
ples were measured by relative quantification (change in expres-
sion in the experimental group vs. control; i.e., untreated vs.
treated cells). The data generated by the ABI Prism 7500 system
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spreadsheet (Excel, Microsoft Corporation, USA), and the experi-
mental values were corrected to that of the cyclophilin A standard
[22,26]. The following oligonucleotides were used: hD1 (5′-AA-
GAGGCTCTGGGTGCTCTTGG-3′ and 5′-GGTTCTGGTGATTTCT-
GATGTC-3′), hD2, 5′-ACTTCCTGCTGGTCTACATTGATG-3′ and 5′-
CTTCCTGGTTCTGGTGCTTCTTC-3′; hD3, 5′-TCCAGAGCCAGCA-
CATCCT-3′ and 5′-ACGTCGCGCTGGTACTTAGTG-3′; cyclophilin A
(internal control), 5′-GTCAACCCCACCGTGTTCTTC-3′ and 5′-
ACTTGCCACCAGTGCCATTATG-3′. The internal control cyclophilin A
was unaffected by the presence of IL6.Fig. 1. Reactive oxygen species (ROS) generation in cells endogenous expressing
type 2 (MSTO; A), type 1 (HepG2; B) or type 3 (MCF-7; C) deiodinases. *Po0.001
refers to the difference between control and IL6 treated (1000 ng/L) while
**Po0.001 refers to the difference between sodium selenite supplementation in
controls as compared with IL6 treated cells. Data are mean7SD of at least three
independent experiments. NAC, N-acetylcysteine.3. Detection of reactive species
Intracellular ROS production was performed by staining cells
with the chloromethyl derivative of 5-(and 6)-chloromethyl-2′7′-
dichlorodihydrofluorescein diacetate (CM-H2-DCFDA) (Invitrogen,
Life Technologies Inc., NY, USA), which can permeate the cell
membrane. This technique is an assay of generalized oxidative
stress rather than of any particular reactive species, and is not a
direct assay of hydrogen peroxide, lipid peroxides, superoxide or
nitric oxide [27]. A stock solution of the dye was reconstituted in
100% DMSO to a concentration of 1 mM immediately before use.
After removing growth medium and washing cells with pre-
warmed phosphate-buffered saline (PBS), 70% confluent MSTO,
HepG2 or MCF-7 cells on six-well plates were incubated at 37 °C
for 30 min with pre-warmed PBS containing CM-H2-DCFDA at a
final concentration of 5 μM. Cells were scraped, centrifuged at
1500 rpm for 3 min, ressuspended and counted. 12,000 cells were
then incubated at 37 °C with 1000 ng/L IL6 in the presence or
absence of 100 mM Na(2)SeO(3) or 20 mM NAC. The same number
of cells was used as negative control. Fluorescence was measured
at wavelengths of 490 nm (excitation) and 535 nm (emission).
Samples were analyzed in triplicate. Data were expressed as fold
increase in fluorescence compared with buffer-treated cells
(control).
3.1. Determination of thioredoxin reductase and peroxide reductase
activity
Thioredoxin reductase activity (TRx) was determined using the
Thioredoxin Reductase Assay Kit (Sigma-Aldrich, St. Louis, MO,
USA) according to the manufacture's instructions. Briefly, after
24 h incubation in the presence or not of IL6, sodium selenite or
n-acetylcysteine cells were lysed with a buffer containing
150 mmol/L NaCl, 50 mmol/L Tris–HCl, 1% Triton X-100, 1% sodium
dodecyl sulfate, 1% deoxycholate, 1 mmol/L NaF and 1 mmol/L
EDTA, and protease inhibitors. After centrifugation at 14,000 g
for 10 min at 4 °C, protein concentrations of supernatants were
determined using the Bradford method, and protein was then in-
cubated in 100 mmol/L of potassium phosphate with 10 mmol/L
EDTA and 0.24 mmol/L NADPH with and without a TRx reductase
inhibitor of all isoforms. The reaction was started by adding 5,5′-
dithiobis(2-nitrobenzoic) acid and monitored spectro-
photometrically at 412 nm. Enzymatic activity was quantified
using the following equation: Unit/mL¼A412 nm/min (thior-
edoxin reductase)dil vol/enzvol (dil¼sample dilution factor;
vol¼volume of reaction in mL; and enzvol¼volume of enzyme in
mL). Results were expressed as U/mg protein.
Glutathione peroxide activity (GPx) was determined using the
Glutathione Peroxidase Cellular Activity Assay Kit (Sigma-Aldrich,
St. Louis, MO, USA) according to the manufacturer's instructions.
Briefly, after 24 h incubation in the presence or not of IL6, sodium
selenite or NAC cells crude homogenate were determined by
monitoring the NADPH disappearance at 340 nm. The specificactivity was calculated as U/mg protein.
3.2. Nonenzymatic antioxidant defenses
Reduced glutathione (GSH) levels were measured after the
same incubation conditions above, according to a standard
method [28]. Briefly, cells in culture dishes were washed with
phosphate-buffered saline (PBS) and harvested in the presence of
300 mL of 20 mM sodium phosphate and 140 mM KCl buffer pH
7.4. Proteins were precipitated by adding sodium metaphosphoric
Fig. 2. Effect of sodium selenite or N-acetylcysteine (NAC) on carbonyl content in
IL6 (1000 ng/L) treated cells endogenous expressing type 2 (MSTO; A), type 1
(HepG2; B) or type 3 (MCF-7; C) deiodinases. Data are mean7SD of at least three
independent experiments. *Po0.001.
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10 min at 7000 g. Fifteen microliters of cell preparation were in-
cubated with an equal volume of o-phthaldialdehyde (1 mg/mL
methanol) at room temperature for 15 min in the presence of 20
volumes (1:20, v/v) of 100 mM sodium phosphate buffer pH 8.0,
containing 5 mM EDTA. Fluorescence was measured using excita-
tion and emission wavelengths of 350 nm and 420 nm, respec-
tively. The calibration curve was performed with standard GSH
(0.001–0.1 mM), and GSH concentrations were calculated as nmol/
mg protein.
Total glutatione (tGS) and oxidized gluthatione (GSSG) con-
centrations were determined by following the enzymatic recycling
method described by Teare et al. (1993) with some modifications.Briefly, cells were homogenized in 4 (w/v) volumes of a solution of
sulfosalicylic acid (11%) and Triton X-100 (0.11%) (1:1 ratio). A brief
incubation of 5 min at 4 °C under continuous shaking was fol-
lowed, the samples were then centrifuged at 10,000 g for 10 min
(4 °C), and the supernatant was collected for analyses of glu-
tathione levels. For GSSG measurement, 10 μL of thes supernatant
were added to 110 μL of a GSH masking buffer (100 mM phosphate
buffer, 1 mM EDTA, 1.1% 2-vinylpyridine), pH 7.4, and incubated for
1 h at room temperature. The samples prepared for tGS and GSSG
were subjected to enzymatic analysis in a recycling buffer system
containing 300 μM NADPH, 225 μM DTNB, 1.6 U/mL GR and
1.0 mM EDTA in 100 mM phosphate buffer (pH 7.4). The linear
increase in absorbance at 405 nm over time was monitored using a
microplate reader (Spectramax M5, Molecular Devices, California,
US). A standard curve was built with known amounts of GSH
(100uM) and GSSG (3.47, 6.95, and 13.89 μM).
3.3. Determination of protein carbonyl content
Duplicate aliquots of 0.3 mg of protein homogenate of each cell
type were incubated with 500 μL of 10 mM 2,4-dinitrophenylhy-
drazine or 1.0 mL of 2 M HCl (blank tube). After 30 min, 250 μL of
50% trichloroacetic acid was added. The samples were centrifuged
at 8000 g for 30 min to obtain protein pellets, which were im-
mediately washed with ethanol–ethyl acetate 1:1 (v/v). The final
protein pellets were resuspended in 500 μL of 8 M urea buffer and
incubated at 50 °C for 90 min. The difference between the 2,4-di-
nitrophenylhydrazine-treated and HCl-treated samples (blank)
was used to calculate the carbonyl content determined at 370 nm.
Carbonyl content was calculated using the millimolar absorption
coefficient of hydrazone (e370 nm¼21,000,000 M1 cm1), and
the results were expressed in nmol carbonyl/mg protein.
3.4. Statistical analysis
Unless otherwise specified, results are presented as mean7SD.
Data were analyzed using two-tailed Student’s t tests or two-way
ANOVA followed by post-hoc Duncan multiple-range tests when F
was significant. Prism 5.0 (GraphPad Software Inc., USA) was used
for statistical analysis; Po0.05 was considered to be statistically
significant.4. Results
4.1. Sodium selenite partially reverses the oxidative stress generated
by IL6
First, we assessed whether sodium selenite had an effect on the
IL6-induced oxidative stress by measuring the amount of in-
tracellular ROS generated. The treatment with NAC (20 mM) was
used as a positive control. Using as reference IL6 levels as observed
in critically ill patients, cells were exposed to 1000 ng/L IL6 [20]
with or without sodium selenite [21]. The experiments were per-
formed using MSTO-211, HepG2 or MCF-7 cell lines, which en-
dogenously express D2 [29], D1 [30], or D3 [30] enzymes, re-
spectively. All cell lines were pre-incubated for 30 min with CM-
H2-DCFDA and then treated with 1000 ng/L IL6 in the presence or
absence of sodium selenite or NAC.
IL6 induced ROS in all 3 cell lines (Po0.001; Fig. 1A–C). Pre-
treatment with sodium selenite slightly attenuated IL6-induced
reactive species detection in MSTO-211, HepG2 and MCF-7 cells
(approximately 25%, 12% and 15%, respectively, all Po0.05;
Fig. 1A–C, respectively) while NAC completely abolished it
(Po0.001; Fig. 1A–C).
Next, we evaluated the amount of carbonyl formation, one of
Fig. 3. Effect of sodium selenite on type 2 deiodinase activity and expression. Sodium selenite does not reverse the inhibitory effect of interleukin IL6 on deiodinase type 2
(D2)-catalyzed T4-to-T3 conversion in endogenous D2 expressing MSTO-211 cells, as observed in the presence of N-acetylcysteine (NAC) (A). The IL6-induced increases on
DIO2 mRNA levels in MSTO-211 cells is not reverted by sodium selenite or NAC (B). *Po0.001, difference between controls and IL6 treated cells; §Po0.001, difference
between controls in the presence or not of sodium selenite. Data are mean7SD of at least three independent experiments. The net iodide release in this system is specific
and equivalent to T3 production.
Fig. 4. Effect of sodium selenite on type 1 deiodinase activity and expression. Sodium selenite does not reverse the inhibitory effect of IL6 on deiodinase type 1 (D1)-
catalyzed T4-to-T3 conversion in HepG2 cells, as observed with NAC (A). The IL6-induced increases on DIO1mRNA levels in HepG2 cells is not reverted by sodium selenite or
NAC (B). *Po0.001, difference between control and IL6 treated cells; §Po0.001, difference between controls in the presence or not of sodium selenite. Data are mean7SD of
at least three independent experiments. The net iodide release in this system is specific and equivalent to T3 production.
Fig. 5. Effect of sodium selenite on type 3 deiodinase activity and expression. Sodium selenite partially reverses the effect of IL6 on deiodinase type 3 (D3) catalyzed T3
inactivation while NAC completely abolishes it (A). There was no effect on the IL6 induced DIO3 messenger RNA (mRNA) (B). *Po0.001, difference between control and IL6
treated cells; **Po0.001, difference between presence or not of sodium selenite; §P¼0.01, difference between controls in the presence or absence of sodium elenite. Data are
mean7SD of at least three independent experiments.
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[13]. In MSTO-211 cells, IL6 induced carbonyl formation (0.03 vs.
1.44 nmol carbonyl/mg protein; Po0.001; Fig. 2A). Pretreatment
with sodium selenite partially corrected the IL6-induced carbonyl
formation, while NAC completely reversed it (1.44 vs. 0.63 vs.
0.08 nmol carbonyl/mg protein, respectively; Po0.001; Fig. 2A). A
similar effect of IL6 on carbonyl formation was observed in HepG2(0.023 vs. 1.24 nmol carbonyl/mg protein, respectively; Po0.001;
Fig. 2B) and MCF-7 cells (0.03 vs. 1.54 nmol carbonyl/mg protein;
Po0.001; Fig. 2C).4.2. Sodium selenite does not prevent the inhibitory effect of IL6 on
Fig. 6. Effect of increasing levels of sodium selenite (0–300 nM) on glutathione
peroxidase activity (A), thioredoxin reductase (TRx) activity (B) and GSH (C) levels
in MSTO-211 (●), HepG2 (▲) or MCF-7 (■) cells. Data are mean7SD of at least three
independent experiments.*Po0.01.
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The conversion of T4-to-T3 by D2 decreases in the presence of
increased levels of IL6 (Fig. 3A). The addition of sodium selenite to
the culture media slightly increased T4-to-T3 conversion in control
cells but failed to prevent the IL6 induced dose-dependent D2
inhibition, as observed with NAC addition (Po0.001; Fig. 3A).
Pretreatment with sodium selenite or NAC did not prevent the IL6-
induced increase in the levels of DIO2 mRNA (Fig. 3B).
Similar experiments were performed using cells expressing
endogenous D1 (HepG2 cells, 30). The addition of sodium selenite
to the culture media slightly increase the conversion of T4-to-T3,
but failed to prevent IL6 induced D1 inhibition (Po0.0001;
Fig. 4A), which was restored in the presence of NAC. As observed
with DIO2, sodium selenite or NAC did not reverse the IL6-induced increase in DIO1 mRNA levels (Fig. 4B).
4.3. Sodium selenite partially reverses the effect of IL6 on D3 activity
Next, we evaluated the effect of sodium selenite on D3 ex-
pression using MCF-7 cells [30]. The addition of IL6 induced D3-
catalyzed T3 inactivation in a dose dependent fashion (Po0.001).
In contrast to the results obtained for D2 and D1, the sodium se-
lenite supplementation attenuated the IL6-induced increase in D3
activity (Po0.05; Fig. 5A). On the other hand, D3 activity return to
the baseline levels with NAC addition. Either sodium selenite or
NAC addition altered the IL6-induced up-regulation of DIO3 mRNA
(Fig. 5B).
4.4. Sodium selenite augments TRx and GPx levels in a dose depen-
dent fashion while it does not change the intracellular GSH
concentrations
To further explore the mechanisms involved on the rescue of
IL6 mediated oxidative changes on deiodinase function, we sought
to evaluate the effect of sodium selenite on the intracellular levels
of GPx and TRx at baseline conditions or under IL6 induced oxi-
dative stress. Total glutathione (tGS), GSH and oxidized glutha-
thione (GSSG) were also evaluated under the same conditions.
Results were compared with those obtained with NAC treatment.
Sodium selenite supplementation increased GPx and TRx ac-
tivities in a dose dependent fashion in all cell lines (Po0.01;
Fig. 6A and B), but it did not alter the intracellular GSH levels (all
P40.05; Fig. 6C).
Next we determined the extension of GPx and TRx consump-
tion in the presence of IL6-induced oxidative stress and whether
sodium selenite supplementation could rescue IL6 mediated ef-
fects. IL6 induced oxidative stress decreased both GPx and TRx
activities in all cell lines whereas sodium selenite counteracted the
IL6 effects (all Po0.05; Fig. 7A–F). NAC had no effect on GPx or
TRx levels (all P40.05; Fig. 7A–F).
We also evaluated the effect of sodium selenite on the non-
enzymatic antioxidant compounds measuring tGS, GSH, and GSSG
levels. Sodium selenite had no effect on IL6 induced effects on tGS,
GSH or GSSG levels whereas NAC reverts all of them (Fig. 8A–I).
Accordingly, IL6-induced oxidative stress results in decreases in
GSH:GSSG ratio in all cell lines (MSTO, 96 vs. 22; MCF-7, 100 vs. 29;
and HepG2, 92 vs. 26; control vs. IL6 treated, respectively, all
Po0.01). The decreases in GSH:GSSG ratio observed in IL6 treated
cells was not reversed by sodium selenite (MSTO, 96 vs. 25; MCF-7,
95 vs. 30; HepG2, 90 vs. 28; control vs. IL6 treated, respectively, all
Po0.01). However, this ratio was completely restore with the
addition of NAC to the medium (MSTO, 96 vs. 123; MCF-7, 114 vs.
114; HepG2 cells, 104–103; control vs. IL6 treated, respectively, all
P40.05).5. Discussion
Perturbations in the intracellular redox status, as observed in
critically ill patients, can disrupt the function of deiodinases. Here,
we have demonstrated that sodium selenite partially corrects the
augmented ROS levels and protein damage generated by patho-
logically elevated concentrations of IL6. However, it does not
prevent the inhibitory effect of IL6 on D2- or D1-catalyzed T3
production while only attenuates the induced D3-catalyzed thyr-
oid hormone inactivation. This might be explained by the lack of
effect of sodium selenite on restoring the intracellular GSH levels,
despite its role as protecting antioxidant enzymes involved in the
intracellular redox balance.
Selenium supplementation has been advised in critically ill
Fig. 7. Effect of sodium selenite or N-acetylcysteine (NAC) on glutathione peroxidase (GPx) and thioredoxin reductase (TRx) activity in controls and IL6 (1000 ng/L) treated
cells. The column on the left shows the effect of sodium selenite or NAC on intracellular GSH levels in controls and IL6 (1000 ng/L) treated MSTO-211 (A), HepG2 (B), or MCF-
7 (C) cells. The column on the right shows the effect of sodium selenite or NAC on intracellular TRx levels in MSTO-211 (D), HepG2 (E), or MCF-7 (F) cells. Data are mean7SD
of at least three independent experiments.
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with oxidative stress, which might lead to the accumulation of
severe damage in proteins, nucleic acids, lipids and other macro-
molecules [8,12,19,31]. Sodium selenite is the most common form
of supplementation of selenium in sick patients. Indeed, in
agreement with clinical studies that show improvement on the
oxidative parameters of critically ill patients [15], here we show in
cell culture model, that the addition of sodium selenite to the
media counteracted 30–50% of the IL6-induced ROS generation
and decreases the formation of carbonyl groups by 50–60% in all
cell lines. Nevertheless, the addition of NAC, an antioxidant that
restores intracellular cysteine and GSH levels, was more effective
in diminishing the IL6 generated ROS and carbonyl formation
(Figs. 1 and 2).
Changes in the intracellular redox state are known to disrupt
deiodinase function [9,10]. The deiodinases are oxireductases that
catalyze iodine removal from the outer or inner ring of thyroid
hormones [32]. The D1 enzyme catalyzed reaction follows ping-
pong kinetics with two substrates, an iodothyronine and a still
unidentified thiol-containing cofactor whereas the D2 and D3
proteins exhibit sequential reaction kinetics, meaning that thesubstrate and the thiol-containing cofactor interact with the en-
zyme simultaneously [33,34]. The putative thiol cofactor(s), critical
for the deiodinase function, may be depleted in situations of oxi-
dative stress, thus impairing the catalytic reactions [12]. Accord-
ingly, NAC prevents the IL6 or H2O2-induced effects on deiodinase
activities as well as changes on thyroid hormone levels as ob-
served in NTIS [9,10,31]. Based on the antioxidant properties of
selenium compounds, one could expect that supplementation
with sodium selenite could also restore deiodinase activity.
Nevertheless, our results show that sodium selenite supple-
mentation did not restore D2 or D1 function (Figs. 3 and 4). In
contrast with the intact cell activity inhibition, IL6-induces an
augment of all deiodinase transcripts, not reversed by sodium
selenite or NAC. Although at first glance contradictory, this ap-
parent discrepancy further indicates impairment of the enzyme
function, probably due to the depletion of the endogenous co-
factor, since the IL6 induced increases in deiodinase mRNAs would
predict a parallel augment in deiodinase activities, as shown in
DTT catalyzed sonicate assays [9]. The IL6 effect probably involves
the p38 MAPK and ERK pathways, since it is abolished by specific
inhibitors [9,35,36], while the MAPK cascades activates cAMP-
Fig. 8. Effect of sodium selenite or N-acetylcysteine (NAC) on total gluthatione (tGS), and GSH and GSSG in controls and IL6 (1000 ng/L) treated cells. The column on the left
shows the effect of sodium selenite or NAC on intracellular tGS levels in controls and IL6 (1000 ng/L) treated MSTO-211 (A), HepG2 (B), or MCF-7 (C) cells. The column on the
middle shows the effect of sodium selenite or NAC on intracellular GSH levels in MSTO-211 (D), HepG2 (E), or MCF-7 (F) cells. The column on the right shows the effect of
sodium selenite or NAC on intracellular GSSG levels in MSTO-211 (D), HepG2 (E), or MCF-7 (F) cells. Data are mean7SD of at least three independent experiments.
S.M. Wajner et al. / Redox Biology 6 (2015) 436–445 443response element-binding protein (CREB), a known inducer of
Dio1, Dio2 and Dio3 gene transcription [35,37]. Interestingly, CREB
has been recently involved in the oxidative-stress response [38].
Other mechanisms besides depletion of a putative thiol co-
factor(s) could be involved on ROS-induced inhibition of deiodi-
nase activity. Upon oxidation, the cysteine residues within proteins
can be modified to different products, including disulfide bonds
and GSH-mixed disulfides [39]. However, the observed derange-
ment of the deiodinase function is probably not due to protein
damage itself. As shown here, notwithstanding the improvement
on the protein related oxidative parameters by sodium selenite
supplementation, it fails to prevent the inhibition on IL6 induced
D2 or D1 activities. Although we cannot rule out other oxidative
stress induced protein modifications that may lead to changes in
deiodinase function, the fact that thiol DTT cofactor addition (in
vitro assays) and NAC treatment fully restore enzyme function
argue against an oxidative damage, post-translational modification
or protein degradation [9].
Remarkably, despite the structural similarities among the
deiodinases, their response to cellular oxidative imbalance appears
to be rather different. Contrasting with the results obtained with
D2 and D1, we observed a partial effect of sodium selenite on IL6-
induced D3 activation (Fig. 5). Although we do not know how toexplain these observations, we speculate that differences in cel-
lular location may explain the different responses of D3 to diverse
oxidative conditions. A still controversial extracellular location of
the catalytic portion of the D3 enzyme [40–42] might have a role
in favoring access to a less oxidative environment due to the
partial correction of redox imbalance secondary to the sodium
selenite supplementation. This hypothesis was previously in-
vestigated by evaluating the effects of IL6 induced decreases on
intracellular GSH levels on transiently expressed D1, D2, or D3 [9].
Interestingly, IL6 decreases D3 activity in a dose dependent fash-
ion. Of note, D3 activity, but not D2 or D1 function, was fully re-
stored by the addition of GSH to the culture media, which might
indicate that extracellular GSH are accessible only for the D3
molecule, overcoming the effects of an intracellular cofactor defi-
ciency [9].
The observed difference in the antioxidant effects of sodium
selenite and NAC on the oxidative stress induced changes on
deiodinase function might be explained by their different me-
chanisms of action. While NAC is the major cysteine donator, not
only to GSH but also to several thiol enzymes, sodium selenite acts
through the GPx and TRx system and does not directly restore
intracellular cysteine/thiol levels [8,12,13,39], which might be
critical to proteins dependent on thiols [8]. Indeed, here we further
S.M. Wajner et al. / Redox Biology 6 (2015) 436–445444demonstrated that, contrasting with NAC, sodium selenite fails to
prevent the IL6 induced decreases in intracellular tGS and GSH
levels (Fig. 7A–F). Taken together, these results support the hy-
pothesis that the inhibition of D2 and D1 functions in an oxidized
environment is mainly due to the depleted amount of endogenous
thiols consumed by ROS.
In conclusion, we demonstrate that sodium selenite partially
corrects the oxidative stress generated by high concentrations of
IL6 but, contrasting with NAC, it does not prevent the IL6-induced
deiodinase dysfunction, which seems to depend on the restoration
of intracellular cysteine levels. These observations add to our
current understanding on NTIS pathogenesis and may explain the
lack of correlation between selenium supplementation and thyroid
hormone levels in critically ill patients [43].Acknowledgement
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